ID   97-24
AC   CVCL_8621
SY   TCC 97-24
DR   Cosmic; 1046699
DR   Cosmic; 1285110
DR   Cosmic; 2037944
DR   Cosmic; 2050435
DR   Cosmic; 2057441
DR   Cosmic; 2444247
DR   Cosmic; 2685936
DR   GEO; GSM1567851
DR   GEO; GSM1574582
DR   GEO; GSM1574589
DR   Wikidata; Q54605817
RX   PubMed=10919661;
RX   PubMed=24018021;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=25997541;
RX   PubMed=29732388;
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
CC   Omics: CNV analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 17
//
RX   PubMed=10919661;
RA   Sarkar S., Julicher K.P., Burger M.S., Della Valle V., Larsen C.-J.,
RA   Yeager T.R., Grossman T.B., Nickells R.W., Protzel C., Jarrard D.F.,
RA   Reznikoff C.A.;
RT   "Different combinations of genetic/epigenetic alterations inactivate
RT   the p53 and pRb pathways in invasive human bladder cancers.";
RL   Cancer Res. 60:3862-3871(2000).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//